Prestige BioPharma Balance Sheet

Financials in millions KRW. Fiscal year is July - June.

Millions KRW. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '24 Jun 30, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020
Cash & Equivalents	219,433	219,433	125,022	268,651	458,975	45,976
Short-Term Investments	9,381	9,381	176,390	25,584	-	2,423
Trading Asset Securities	-	-	-	9,035	377.68	-
Cash & Short-Term Investments	228,815	228,815	301,412	303,270	459,353	48,399
Cash Growth	-24.09%	-24.09%	-0.61%	-33.98%	849.10%	-
Receivables	391.6	391.6	132.72	-	-	-
Inventory	18,103	18,103	7,146	2,157	-	-
Prepaid Expenses	2,733	2,733	2,731	-	-	1,412
Other Current Assets	309.41	309.41	53.44	6,139	584.08	-
Total Current Assets	250,352	250,352	311,476	311,566	459,937	49,811
Property, Plant & Equipment	327,062	327,062	310,438	38,342	6,437	4,519
Long-Term Investments	-	-	-	74,710	24,159	9,049
Goodwill	10,785	10,785	10,192	-	-	-
Other Intangible Assets	31,327	31,327	29,877	4,288	450.33	386.92
Long-Term Deferred Charges	91,643	91,643	78,843	61,024	108,573	94,624
Other Long-Term Assets	551.5	551.5	775.14	9,883	4,611	1,709
Total Assets	711,720	711,720	741,600	499,813	604,166	160,098
Accounts Payable	2,282	2,282	462.15	2,624	-	-
Accrued Expenses	5,975	5,975	6,150	4,923	3,552	1,099
Short-Term Debt	15,439	15,439	31,188	-	2,873	-
Current Portion of Long-Term Debt	47,845	47,845	31,176	-	-	-
Current Portion of Leases	950.81	950.81	1,682	1,593	1,326	443.84
Current Unearned Revenue	-	-	-	-	565	231.5
Other Current Liabilities	73,366	73,366	64,231	32,654	5,730	6,702
Total Current Liabilities	145,857	145,857	134,888	41,794	14,046	8,477
Long-Term Debt	40,247	40,247	50,190	-	-	61.26
Long-Term Leases	624.04	624.04	1,326	2,656	3,571	2,373
Long-Term Unearned Revenue	-	-	-	25,427	11,588	11,387
Long-Term Deferred Tax Liabilities	7,755	7,755	7,368	-	-	-
Other Long-Term Liabilities	1,734	1,734	1,593	0	-	-
Total Liabilities	196,219	196,219	195,365	69,877	29,206	22,299
Common Stock	730,340	730,340	690,175	679,713	594,072	152,779
Additional Paid-In Capital	7,865	7,865	7,286	7,175	-	-
Retained Earnings	-294,797	-294,797	-246,151	-259,601	-27,954	-21,891
Comprensive Income & Other	-4,321	-4,321	-798.76	2,649	8,843	6,911
Total Common Equity	439,087	439,087	450,511	429,936	574,961	137,799
Minority Interest	76,414	76,414	95,724	-	-	-
Shareholders' Equity	515,502	515,502	546,235	429,936	574,961	137,799
Total Liabilities & Equity	711,720	711,720	741,600	499,813	604,166	160,098
Total Debt	105,106	105,106	115,561	4,249	7,771	2,878
Net Cash (Debt)	123,708	123,708	185,851	299,020	451,582	45,521
Net Cash Growth	-33.44%	-33.44%	-37.85%	-33.78%	892.04%	-
Net Cash Per Share	2058.50	2058.50	3092.56	4975.70	8751.18	1067.23
Filing Date Shares Outstanding	300.48	300.48	300.48	300.48	300.48	44.71
Total Common Shares Outstanding	300.48	300.48	300.48	300.48	300.48	44.71
Working Capital	104,494	104,494	176,588	269,771	445,890	41,335
Book Value Per Share	1461.28	1461.28	1499.30	1430.83	1913.47	3082.31
Tangible Book Value	396,976	396,976	410,442	425,647	574,510	137,413
Tangible Book Value Per Share	1321.13	1321.13	1365.95	1416.55	1911.97	3073.66
Land	27,704	27,704	26,567	12,055	-	-
Buildings	77,472	77,472	76,415	-	-	-
Machinery	72,427	72,427	51,848	10,175	3,455	2,809
Construction In Progress	152,876	152,876	169,147	15,415	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.